Evaluation and management of chronic cough in adults.

IF 2.6 3区 医学 Q2 ALLERGY Allergy and asthma proceedings Pub Date : 2023-11-01 DOI:10.2500/aap.2023.44.230059
Dana V Wallace
{"title":"Evaluation and management of chronic cough in adults.","authors":"Dana V Wallace","doi":"10.2500/aap.2023.44.230059","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Chronic cough (CC), a cough that lasts > 8 weeks, has an overall prevalence of 5-11% in adults, peaking between 60 and 80 years of age. Of the 15% of patients who remain undiagnosed or refractory to treatment, two thirds are women. <b>Objective:</b> The objective was to present an updated evidence-based algorithmic approach for evaluating and managing CC, with emphasis on treatment modalities for refractory CC. <b>Methods:</b> A literature search was conducted of medical literature data bases for guidelines, position papers, systematic reviews, and clinical trials from January 2022 to June 2023, on the evaluation and management of CC. <b>Results:</b> The initial assessment should be limited to a detailed history, physical examination, chest radiograph, spirometry, exhaled nitric oxide, blood eosinophil count, and measurement of cough severity and quality of life by using validated instruments. The top diagnoses to consider are asthma, chronic obstructive pulmonary disease, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airway cough syndrome. Additional studies are only obtained when red flags are present or the patient fails to respond after avoidance of high-risk factors, e.g., smoking and angiotensin-converting enzyme inhibitors, and 4-6 weeks of empiric treatment for the most likely respiratory and gastrointestinal diseases. When diagnostic tests and/or specific directed treatments fail to control CC, low-dose morphine (preferred), gabapentin, pregabalin, and/or cough control therapy are recommended. Non-narcotic purinergic 2×3 (P2×3) receptor antagonists, gafapixant and campilixant, are currently being studied for CC. <b>Conclusion:</b> For the evaluation and management of patients with CC, clinicians should use an algorithmic approach and identify \"red flags,\" reduce high-risk factors, and use empiric treatment for the five top diagnoses before extensive diagnostic testing. Current treatment for refractory cough is limited to symptomatic management.</p>","PeriodicalId":7646,"journal":{"name":"Allergy and asthma proceedings","volume":"44 6","pages":"382-394"},"PeriodicalIF":2.6000,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy and asthma proceedings","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2500/aap.2023.44.230059","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Chronic cough (CC), a cough that lasts > 8 weeks, has an overall prevalence of 5-11% in adults, peaking between 60 and 80 years of age. Of the 15% of patients who remain undiagnosed or refractory to treatment, two thirds are women. Objective: The objective was to present an updated evidence-based algorithmic approach for evaluating and managing CC, with emphasis on treatment modalities for refractory CC. Methods: A literature search was conducted of medical literature data bases for guidelines, position papers, systematic reviews, and clinical trials from January 2022 to June 2023, on the evaluation and management of CC. Results: The initial assessment should be limited to a detailed history, physical examination, chest radiograph, spirometry, exhaled nitric oxide, blood eosinophil count, and measurement of cough severity and quality of life by using validated instruments. The top diagnoses to consider are asthma, chronic obstructive pulmonary disease, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airway cough syndrome. Additional studies are only obtained when red flags are present or the patient fails to respond after avoidance of high-risk factors, e.g., smoking and angiotensin-converting enzyme inhibitors, and 4-6 weeks of empiric treatment for the most likely respiratory and gastrointestinal diseases. When diagnostic tests and/or specific directed treatments fail to control CC, low-dose morphine (preferred), gabapentin, pregabalin, and/or cough control therapy are recommended. Non-narcotic purinergic 2×3 (P2×3) receptor antagonists, gafapixant and campilixant, are currently being studied for CC. Conclusion: For the evaluation and management of patients with CC, clinicians should use an algorithmic approach and identify "red flags," reduce high-risk factors, and use empiric treatment for the five top diagnoses before extensive diagnostic testing. Current treatment for refractory cough is limited to symptomatic management.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
成人慢性咳嗽的评估和治疗。
背景:慢性咳嗽(CC)是一种持续8周以上的咳嗽,在成年人中的总体患病率为5-11%,在60至80岁之间达到峰值。在15%的未确诊或难以治疗的患者中,三分之二是女性。目的:目的是提出一种更新的基于证据的算法方法来评估和管理CC,重点是难治性CC的治疗模式。方法:从2022年1月至2023年6月,对医学文献数据库中关于CC评估和管理的指南、立场文件、系统综述和临床试验进行文献检索。结果:初步评估应限于详细的病史、体格检查、胸部X线片、肺活量测定、呼出一氧化氮、血液嗜酸性粒细胞计数,以及使用经验证的仪器测量咳嗽严重程度和生活质量。最需要考虑的诊断是哮喘、慢性阻塞性肺病、非哮喘性嗜酸性支气管炎、胃食管反流病和上呼吸道咳嗽综合征。只有当出现危险信号或患者在避免高危因素(如吸烟和血管紧张素转换酶抑制剂)以及对最可能的呼吸道和胃肠道疾病进行4-6周的经验性治疗后没有反应时,才能获得额外的研究。当诊断测试和/或特定的定向治疗无法控制CC时,建议使用低剂量吗啡(首选)、加巴喷丁、普瑞巴林和/或咳嗽控制治疗。目前正在研究非麻醉性嘌呤能2×3(P2×3)受体拮抗剂加法哌吨和坎皮利吨治疗CC。结论:对于CC患者的评估和管理,临床医生应该使用算法方法,识别“危险信号”,减少高危因素,并在广泛的诊断测试之前对五种顶级诊断进行经验性治疗。目前顽固性咳嗽的治疗仅限于症状治疗。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
5.70
自引率
35.70%
发文量
106
审稿时长
6-12 weeks
期刊介绍: Allergy & Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists. The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma. Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
期刊最新文献
Management of hereditary angioedema attacks by patients on long-term prophylaxis versus on-demand therapy only. Real-world surveillance of standardized quality (SQ) house dust mite sublingual immunotherapy tablets for 3 years in Japan. A case of a rash after tetanus-diphtheria-pertussis and meningococcal vaccination. Eating increases disease activity in pediatric patients with symptomatic dermographism. A systematic review and meta-analysis exploring the bidirectional association between asthma and gastroesophageal reflux disease in children.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1